OXER1

Summary

OXER1 (oxoeicosanoid receptor 1, HGNC:24884) is a protein-coding gene on chromosome 2p21, encoding Oxoeicosanoid receptor 1 (Q8TDS5). Receptor for eicosanoids and polyunsaturated fatty acids such as 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-OXO-ETE), 5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HPETE) and arachidonic acid.

Enables G protein-coupled receptor activity and icosanoid binding activity. Involved in adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway. Predicted to be located in membrane. Predicted to be active in plasma membrane.

Source: NCBI Gene 165140 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 109 total — 1 pathogenic
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_148962

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24884
Approved symbol	OXER1
Name	oxoeicosanoid receptor 1
Location	2p21
Locus type	gene with protein product
Status	Approved
Aliases	GPCR, TG1019, GPR170
Ensembl gene	ENSG00000162881
Ensembl biotype	protein_coding
OMIM	620064
Entrez	165140

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000378661

RefSeq mRNA: 1 — MANE Select: NM_148962 NM_148962

CCDS: CCDS1810

Canonical transcript exons

ENST00000378661 — 1 exons

Exon	Start	End
ENSE00001478276	42762499	42764135

Expression profiles

Bgee: expression breadth ubiquitous, 155 present calls, max score 90.79.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.7244 / max 137.4396, expressed in 147 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
28023	0.5619	122
28021	0.1072	51
28022	0.0553	23

Top tissues by expression

243 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	90.79	gold quality
mucosa of transverse colon	UBERON:0004991	84.89	gold quality
liver	UBERON:0002107	78.93	gold quality
blood	UBERON:0000178	78.39	gold quality
right ovary	UBERON:0002118	77.05	gold quality
granulocyte	CL:0000094	76.87	gold quality
left ovary	UBERON:0002119	76.65	gold quality
small intestine Peyer’s patch	UBERON:0003454	76.15	gold quality
leukocyte	CL:0000738	75.40	gold quality
monocyte	CL:0000576	75.20	gold quality
small intestine	UBERON:0002108	74.27	gold quality
body of pancreas	UBERON:0001150	73.81	gold quality
ascending aorta	UBERON:0001496	71.97	gold quality
thoracic aorta	UBERON:0001515	71.70	gold quality
ovary	UBERON:0000992	71.62	gold quality
metanephros cortex	UBERON:0010533	71.45	gold quality
adult mammalian kidney	UBERON:0000082	71.25	gold quality
descending thoracic aorta	UBERON:0002345	71.14	gold quality
bone marrow cell	CL:0002092	70.56	gold quality
endocervix	UBERON:0000458	70.21	gold quality
mucosa of stomach	UBERON:0001199	70.15	gold quality
ectocervix	UBERON:0012249	69.91	gold quality
transverse colon	UBERON:0001157	69.71	gold quality
body of uterus	UBERON:0009853	69.71	gold quality
cortex of kidney	UBERON:0001225	69.64	gold quality
spleen	UBERON:0002106	69.37	gold quality
right coronary artery	UBERON:0001625	68.96	gold quality
bone marrow	UBERON:0002371	68.67	gold quality
sural nerve	UBERON:0015488	68.58	gold quality
aorta	UBERON:0000947	68.43	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.89

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

9 targeting OXER1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-4722-3P	99.35	65.22	1099
HSA-MIR-6780B-3P	99.13	67.18	622
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-6801-3P	98.04	64.64	805
HSA-MIR-4303	98.01	68.13	2304
HSA-MIR-6810-3P	97.96	64.57	1023
HSA-MIR-3690	96.44	65.18	737

Literature-anchored findings (GeneRIF, showing 11)

• Identification of a novel human receptor coupled to G(i/o). (PMID:12065583)
• identification and cloning of a novel GPCR, R527; 5-oxo-ETE was identified as the ligand for R527; very high level of mRNA expression in eosinophils with high expression also detected in neutrophils and lung macrophages (PMID:12606753)
• 5-oxoER is critical for prostate cancer cell survival. (PMID:16289380)
• OXER1 has a role in regulating the survival-promoting effects of arachidonate 5-lipoxygenase in prostate cancer cells (PMID:23643940)
• Gue1654 as a non-Galphai-biased antagonist of OXE-R that provides a new basis for therapeutic intervention in inflammatory diseases that involve activation of eosinophils, neutrophils, and monocytes. (PMID:24733850)
• membrane receptor OxeR1 is involved in StAR protein induction and activation of steroidogenesis triggered by cAMP or angiotensin II, acting, at least in part, through ERK1/2 activation. (PMID:25657046)
• These findings verify that membrane-acting androgens exert specific effects through an antagonistic interaction with OXER1. Additionally, this interaction between androgen and OXER1, which is an arachidonic acid metabolite receptor expressed in prostate cancer, provides a novel link between steroid and lipid actions and renders OXER1 as new player in the disease. (PMID:28290516)
• The G protein coupled oxo-eicosanoid receptor 1 (OXER1) (a receptor of the arachidonic acid metabolite, 5-oxoeicosatetraenoic acid, 5-oxoETE) is as a novel mAR involved in the rapid effects of androgens. (PMID:30707908)
• OXER1 mediates testosterone-induced calcium responses in prostate cancer cells. (PMID:34634385)
• Enhanced OXER1 expression is indispensable for human cancer cell migration. (PMID:34775286)
• Biological Roles of 5-Oxo-6,8,11,14-Eicosatetraenoic Acid and the OXE Receptor in Allergic Diseases: Collegium Internationale Allergologicum Update 2024. (PMID:38176394)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	hcar1-3	ENSDARG00000062874
danio_rerio	hcar1-4	ENSDARG00000087084

Paralogs (15): GPR31 (ENSG00000120436), GPR42 (ENSG00000126251), FFAR2 (ENSG00000126262), FFAR1 (ENSG00000126266), OXGR1 (ENSG00000165621), P2RY1 (ENSG00000169860), P2RY6 (ENSG00000171631), GPR82 (ENSG00000171657), P2RY2 (ENSG00000175591), HCAR2 (ENSG00000182782), FFAR3 (ENSG00000185897), P2RY4 (ENSG00000186912), HCAR1 (ENSG00000196917), SUCNR1 (ENSG00000198829), HCAR3 (ENSG00000255398)

Protein

Protein identifiers

Oxoeicosanoid receptor 1 — Q8TDS5 (reviewed: Q8TDS5)

Alternative names: 5-oxo-ETE G-protein coupled receptor, G-protein coupled receptor 170, G-protein coupled receptor R527, G-protein coupled receptor TG1019

All UniProt accessions (1): Q8TDS5

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for eicosanoids and polyunsaturated fatty acids such as 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-OXO-ETE), 5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HPETE) and arachidonic acid. Seems to be coupled to the G(i)/G(o), families of heteromeric G proteins.

Subcellular location. Membrane.

Tissue specificity. Expressed in various tissues except brain. Expression is more intense in liver, kidney, peripheral leukocyte, lung, and spleen than in other tissues. Highly expressed in eosinophils, neutrophils, and lung macrophages.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_683765* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR051893	HCARs	Family

Pfam: PF00001

UniProt features (22 total): topological domain 8, transmembrane region 7, sequence variant 2, chain 1, region of interest 1, compositionally biased region 1, glycosylation site 1, disulfide bond 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TDS5-F1	82.24	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 126–198

Glycosylation sites (1): 5

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-391903	Eicosanoid ligand-binding receptors
R-HSA-418594	G alpha (i) signalling events

MSigDB gene sets: 32 (showing top): REACTOME_EICOSANOID_LIGAND_BINDING_RECEPTORS, GOBP_ADENYLATE_CYCLASE_MODULATING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOBP_ADENYLATE_CYCLASE_INHIBITING_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOMF_LONG_CHAIN_FATTY_ACID_BINDING, GOMF_FATTY_ACID_BINDING, REACTOME_CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, GOMF_ORGANIC_ACID_BINDING, GOMF_LIPID_BINDING, GOMF_MONOCARBOXYLIC_ACID_BINDING, GOMF_G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY, KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN, MARTENS_TRETINOIN_RESPONSE_UP, GOBP_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOMF_ICOSANOID_BINDING

GO Biological Process (3): G protein-coupled receptor signaling pathway (GO:0007186), adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway (GO:0007193), signal transduction (GO:0007165)

GO Molecular Function (5): G protein-coupled receptor activity (GO:0004930), 5-oxo-6E,8Z,11Z,14Z-icosatetraenoic acid binding (GO:0050646), 5-hydroxy-6E,8Z,11Z,14Z-icosatetraenoic acid binding (GO:0050647), 5(S)-hydroxyperoxy-6E,8Z,11Z,14Z-icosatetraenoic acid binding (GO:0050648), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Class A/1 (Rhodopsin-like receptors)	1
GPCR downstream signalling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
long-chain fatty acid binding	3
icosanoid binding	3
fatty acid derivative binding	2
G protein-coupled receptor activity	1
signal transduction	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase inhibitor activity	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

508 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OXER1	GPRC6A	Q5T6X5	622
OXER1	SLC39A9	Q9NUM3	621
OXER1	LTB4R2	Q9NPC1	513
OXER1	ALOX5	P09917	507
OXER1	TRPM8	Q7Z2W7	398
OXER1	GPR148	Q8TDV2	380
OXER1	ALOX5AP	P20292	348
OXER1	OR4D1	Q15615	320
OXER1	NPB	Q8NG41	312
OXER1	OR2A14	Q96R47	312
OXER1	TAS2R4	Q9NYW5	300
OXER1	ZNF786	Q8N393	297
OXER1	ALOX12	P18054	270
OXER1	ZNF30	P17039	268
OXER1	MRGPRD	Q8TDS7	267
OXER1	TRHR	P34981	267

IntAct

135 interactions, top by confidence:

A	B	Type	Score
LASP1	OXER1	psi-mi:“MI:0915”(physical association)	0.560
RECK	OXER1	psi-mi:“MI:0915”(physical association)	0.560
OXER1	ASB13	psi-mi:“MI:0915”(physical association)	0.560
OXER1	TFG	psi-mi:“MI:0915”(physical association)	0.560
PRR20D	OXER1	psi-mi:“MI:0915”(physical association)	0.560
EFCAB3	OXER1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP19-5	OXER1	psi-mi:“MI:0915”(physical association)	0.560
CRYBA2	OXER1	psi-mi:“MI:0915”(physical association)	0.560
TP53BP1	OXER1	psi-mi:“MI:0915”(physical association)	0.560
TLE5	OXER1	psi-mi:“MI:0915”(physical association)	0.560
OXER1	PLSCR4	psi-mi:“MI:0915”(physical association)	0.560
OXER1	ANAPC11	psi-mi:“MI:0915”(physical association)	0.560
OXER1	RNF38	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	OXER1	psi-mi:“MI:0915”(physical association)	0.560
ZIC1	OXER1	psi-mi:“MI:0915”(physical association)	0.560
OXER1	ZC3H10	psi-mi:“MI:0915”(physical association)	0.560
HNF1B	OXER1	psi-mi:“MI:0915”(physical association)	0.560
OTX1	OXER1	psi-mi:“MI:0915”(physical association)	0.560
CCNK	OXER1	psi-mi:“MI:0915”(physical association)	0.560
FOXH1	OXER1	psi-mi:“MI:0915”(physical association)	0.560
RNF44	OXER1	psi-mi:“MI:0915”(physical association)	0.560
VGLL3	OXER1	psi-mi:“MI:0915”(physical association)	0.560
HNRNPH1	OXER1	psi-mi:“MI:0915”(physical association)	0.560
OXER1	KRTAP4-2	psi-mi:“MI:0915”(physical association)	0.560
PRKAB2	OXER1	psi-mi:“MI:0915”(physical association)	0.560
PROP1	OXER1	psi-mi:“MI:0915”(physical association)	0.560
OXER1	RAMAC	psi-mi:“MI:0915”(physical association)	0.560
ESRP1	OXER1	psi-mi:“MI:0915”(physical association)	0.560
INTS11	OXER1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP12-3	OXER1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (50): ARRB2 (FRET), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid), OXER1 (Two-hybrid)

ESM2 similar proteins: A0A6I8PUB9, O00155, O00270, O14842, O14843, O15529, O43603, O46685, O60755, O88626, O88634, O88853, O88854, O88855, P0C5I1, P46092, P46093, P50132, Q149R9, Q15722, Q15743, Q1JQB3, Q3T181, Q3UFD7, Q3ZC80, Q4KLH9, Q6XKD3, Q76JU8, Q76JU9, Q76JV1, Q86VZ1, Q8BUD0, Q8BYC4, Q8HYC3, Q8K3T4, Q8TDS5, Q8TDU9, Q920E0, Q924U0, Q96G91

Diamond homologs: A0A6I8PUB9, E9QJ73, F8VQN3, O00270, O09047, O42179, O55197, P21109, P25024, P25025, P35344, P35383, P41231, P41232, P46092, P49019, P55920, P97266, Q15722, Q16581, Q28003, Q28422, Q28519, Q28807, Q2KI97, Q2YEG0, Q5REI5, Q5YA25, Q6TAC8, Q80Z39, Q8C131, Q8CIM5, Q8SQ54, Q8TDS4, Q8TDS5, Q96G91, Q99PE3, Q9BXC0, Q9EP66, Q9JL21

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
“diisononyl phthalate”	“up-regulates activity”	OXER1	“chemical activation”
“mono(2-ethylhexyl) phthalate”	“up-regulates activity”	OXER1	“chemical activation”
“monoisononyl phthalate”	“up-regulates activity”	OXER1	“chemical activation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 46 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	5	9.3×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

109 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	97
Likely benign	9
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
59144	GRCh38/hg38 2p21(chr2:41999414-42915744)x3	Pathogenic

SpliceAI

69 predictions. Top by Δscore:

Variant	Effect	Δscore
2:42763597:C:CT	donor_gain	0.8300
2:42763598:C:CT	donor_gain	0.8200
2:42763593:TGCAC:T	donor_gain	0.6800
2:42763596:A:AC	donor_gain	0.6300
2:42763599:A:AA	donor_gain	0.4800
2:42763462:AGCTG:A	acceptor_gain	0.4700
2:42764104:TTC:T	donor_gain	0.4600
2:42764105:TCT:T	donor_gain	0.4600
2:42763268:G:GT	acceptor_gain	0.4500
2:42763269:T:TT	acceptor_gain	0.4500
2:42763595:CA:C	donor_gain	0.4500
2:42763579:G:C	donor_gain	0.4000
2:42763543:C:CT	donor_gain	0.3400
2:42763463:GCT:G	acceptor_gain	0.3300
2:42763818:G:GC	acceptor_gain	0.3300
2:42763572:CGG:C	donor_gain	0.3200
2:42763362:A:AC	donor_gain	0.3100
2:42763363:C:CC	donor_gain	0.3100
2:42763583:G:C	donor_gain	0.3100
2:42763594:GCACC:G	donor_gain	0.3100
2:42763815:CGCG:C	acceptor_gain	0.3100
2:42763818:G:C	acceptor_gain	0.3100
2:42763911:A:T	acceptor_gain	0.3000
2:42762661:G:A	donor_gain	0.2900
2:42763279:C:CT	donor_gain	0.2900
2:42763267:TG:T	acceptor_gain	0.2800
2:42763814:CCGCG:C	acceptor_gain	0.2800
2:42763317:G:A	donor_gain	0.2700
2:42763456:C:CA	acceptor_gain	0.2600
2:42763544:C:CT	donor_gain	0.2600

AlphaMissense

2705 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:42763256:G:C	F308L	0.982
2:42763256:G:T	F308L	0.982
2:42763258:A:G	F308L	0.982
2:42763247:G:C	S311R	0.979
2:42763247:G:T	S311R	0.979
2:42763249:T:G	S311R	0.979
2:42763781:G:C	S133R	0.977
2:42763781:G:T	S133R	0.977
2:42763783:T:G	S133R	0.977
2:42763136:A:C	S348R	0.975
2:42763136:A:T	S348R	0.975
2:42763138:T:G	S348R	0.975
2:42763706:C:A	W158C	0.973
2:42763706:C:G	W158C	0.973
2:42763766:G:C	D138E	0.970
2:42763766:G:T	D138E	0.970
2:42763397:G:C	F261L	0.960
2:42763397:G:T	F261L	0.960
2:42763399:A:G	F261L	0.960
2:42763169:G:C	F337L	0.959
2:42763169:G:T	F337L	0.959
2:42763171:A:G	F337L	0.959
2:42763643:G:C	S179R	0.954
2:42763643:G:T	S179R	0.954
2:42763645:T:G	S179R	0.954
2:42763127:G:C	D351E	0.947
2:42763127:G:T	D351E	0.947
2:42763847:A:C	S111R	0.945
2:42763847:A:T	S111R	0.945
2:42763849:T:G	S111R	0.945

dbSNP variants (sampled 300 via entrez): RS1000825883 (2:42765088 C>G), RS1001198392 (2:42762293 G>A), RS1001260527 (2:42762794 G>A), RS1001605615 (2:42762986 A>G), RS1001793778 (2:42762535 A>G), RS1005124017 (2:42764692 G>C), RS1005239951 (2:42762319 C>T), RS1006024291 (2:42764438 C>G), RS1006752576 (2:42765993 A>G), RS1006913389 (2:42763212 C>T), RS1007441979 (2:42765081 C>T), RS1007577480 (2:42764820 A>G), RS1007944333 (2:42762923 G>A,C), RS1008003253 (2:42762521 T>C), RS1008580311 (2:42765862 T>C)

Disease associations

OMIM: gene MIM:620064 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000278_1	Hyperactive-impulsive symptoms	2.000000e-06
GCST000281_1	Attention deficit hyperactivity disorder	6.000000e-06
GCST002715_2	Breastfeeding duration	1.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006864	breastfeeding duration

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1628461 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 126,019 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL367149	DOCONEXENT	3	63,817
CHEMBL460026	ICOSAPENT	3	60,180
CHEMBL465183	DIHOMO-GAMMA-LINOLENIC ACID	2	2,022

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Leukotriene receptors

Most potent curated ligand interactions (12 total), top 12:

Ligand	Action	Affinity	Parameter
S‐Y048	Antagonist	10.7	pIC50
5-oxo-ETE	Full agonist	8.5	pEC50
[3H]5-oxo-ETE	Agonist	8.4	pKd
5-oxo-C20:3	Full agonist	8.0	pEC50
5-oxo-ODE	Full agonist	8.0	pEC50
5-oxo-15-HETE	Full agonist	7.7	pEC50
5S-HETE	Full agonist	7.2	pEC50
5S-HPETE	Full agonist	7.0	pEC50
5-oxo-20-HETE	Full agonist	6.5	pEC50
5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid	Antagonist	6.4	pIC50
5-oxo-12-HETE	Antagonist	6.3	pIC50
Gue1654	Negative	6.0	pIC50

Binding affinities (BindingDB)

2 measured of 3 human assays (3 total across all organisms); most potent 2 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
(Z,Z,Z)-8,11,14-Eicosatrienoic acid	KI	3700 nM
5,8,11,14,17-EICOSAPENTAENOIC ACID	KI	6000 nM

ChEMBL bioactivities

84 potent at pChembl≥5 of 91 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.92	IC50	0.12	nM	CHEMBL4283608
9.55	IC50	0.28	nM	CHEMBL4287941
9.42	IC50	0.38	nM	CHEMBL4281149
8.68	IC50	2.1	nM	CHEMBL4282356
8.66	IC50	2.2	nM	CHEMBL3341973
8.57	IC50	2.7	nM	CHEMBL3341971
8.52	IC50	3	nM	5-OXO-ETE
8.22	IC50	6	nM	CHEMBL3115775
8.22	IC50	6	nM	CHEMBL3341972
8.15	IC50	7	nM	CHEMBL3115774
8.15	EC50	7	nM	5-OXO-ETE
8.12	IC50	7.5	nM	CHEMBL1760545
7.96	IC50	11	nM	CHEMBL4284672
7.92	IC50	12	nM	CHEMBL4277299
7.80	IC50	16	nM	CHEMBL3115775
7.77	IC50	17	nM	CHEMBL3115775
7.77	IC50	17	nM	CHEMBL3115774
7.75	IC50	18	nM	CHEMBL3115774
7.75	IC50	18	nM	CHEMBL4291346
7.64	IC50	23	nM	CHEMBL4084871
7.64	IC50	23	nM	CHEMBL4291464
7.58	IC50	26	nM	CHEMBL3115793
7.55	IC50	28	nM	CHEMBL3115775
7.55	IC50	28	nM	CHEMBL3115774
7.52	IC50	30	nM	CHEMBL3115774
7.52	IC50	30	nM	CHEMBL3115786
7.48	IC50	33	nM	CHEMBL3115775
7.42	IC50	38	nM	CHEMBL4278772
7.42	IC50	38	nM	CHEMBL4279605
7.25	EC50	56	nM	CHEMBL1682258
7.17	EC50	67	nM	5-OXO-ETE
7.09	IC50	81	nM	CHEMBL3115792
7.05	IC50	90	nM	CHEMBL3115782
6.92	IC50	120	nM	CHEMBL4277207
6.87	IC50	136	nM	CHEMBL3115783
6.85	IC50	141	nM	CHEMBL3115785
6.68	IC50	210	nM	CHEMBL4280693
6.66	EC50	220	nM	5-OXO-ETE
6.65	IC50	223	nM	CHEMBL4287509
6.58	IC50	260	nM	CHEMBL4285167
6.50	IC50	314	nM	CHEMBL3115791
6.49	IC50	323	nM	CHEMBL3115787
6.42	EC50	380	nM	CHEMBL4127146
6.40	IC50	400	nM	CHEMBL2332562
6.40	IC50	402	nM	CHEMBL3115774
6.34	IC50	454	nM	CHEMBL3115775
6.34	IC50	460	nM	CHEMBL3311230
6.30	IC50	500	nM	CHEMBL3115778
6.30	IC50	500	nM	CHEMBL1526258
6.26	IC50	550	nM	CHEMBL3115800

PubChem BioAssay actives

84 with measured affinity, of 149 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(3S)-5-[5-chloro-1-methyl-2-(6-phenylhexyl)indol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0001	uM
5-[5-chloro-1-methyl-2-(6-phenylhexyl)indol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0003	uM
(3S)-5-[5-chloro-2-[(1S)-1-hydroxy-6-phenylhexyl]-1-methylindol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0004	uM
5-[6-chloro-2-(5-phenylpentyl)indol-1-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0021	uM
(3S)-5-(6-chloro-2-hexylindol-1-yl)-3-methyl-5-oxopentanoic acid	1185137: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of calcium mobilization by fluorescence assay	ic50	0.0022	uM
(3R)-5-(5-chloro-2-hexyl-1-methylindol-3-yl)-3-methyl-5-oxopentanoic acid	1185137: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of calcium mobilization by fluorescence assay	ic50	0.0027	uM
(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoic acid	590219: Desensitization of 5-oxo-ETE receptor in indo-1-labeled human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization	ic50	0.0030	uM
(3S)-5-(5-chloro-2-hexyl-1-methylindol-3-yl)-3-methyl-5-oxopentanoic acid	1185137: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of calcium mobilization by fluorescence assay	ic50	0.0060	uM
5-(5-chloro-2-hexyl-1-methylindol-3-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.0060	uM
5-(6-chloro-2-hexylindol-1-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.0070	uM
(6E,8Z,11Z,14Z)-20,20,20-trifluoro-5-oxoicosa-6,8,11,14-tetraenoic acid	590219: Desensitization of 5-oxo-ETE receptor in indo-1-labeled human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization	ic50	0.0075	uM
5-[5-chloro-1-methyl-2-(5-phenylpentyl)indol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0110	uM
5-[6-chloro-2-(6-phenylhexyl)indol-1-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0120	uM
5-[6-chloro-2-(4-phenylbutyl)indol-1-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0180	uM
(3R)-5-[5-chloro-1-methyl-2-(6-phenylhexyl)indol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0230	uM
5-(5-chloro-1-methyl-2-undecylindol-3-yl)-3-methyl-5-oxopentanoic acid	1464785: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0230	uM
5-(5-bromo-2-hexyl-1-methylindol-3-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.0260	uM
5-(6-bromo-2-hexylindol-1-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.0300	uM
5-[5-chloro-1-methyl-2-(4-phenylbutyl)indol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0380	uM
5-[5-chloro-1-methyl-2-(6,6,6-trifluorohexyl)indol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.0380	uM
(6E,8Z,11Z,13E,15S)-15-hydroxy-5-oxoicosa-6,8,11,13-tetraenoic acid	579486: Agonist activity at 5-oxo-ETE receptor in human neutrophils assessed as stimulation of ca2+ mobilization	ec50	0.0560	uM
5-(6-chloro-2-hexyl-1-methylindol-3-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.0810	uM
5-(2-hexylindol-1-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.0900	uM
(3R)-5-[5-chloro-2-[(1S)-1-hydroxy-6-phenylhexyl]-1-methylindol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.1200	uM
5-(2-hexyl-3-methylindol-1-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.1360	uM
5-(5-chloro-2-hexylindol-1-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.1410	uM
5-[6-chloro-2-(3-phenylpropyl)indol-1-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.2100	uM
5-[5-chloro-1-methyl-2-(3-phenylpropyl)indol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.2230	uM
(3S)-5-[5-chloro-2-[(1R)-1-hydroxy-6-phenylhexyl]-1-methylindol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.2600	uM
5-(2-hexyl-1-methylindol-3-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.3140	uM
5-(2-hexyl-6-methoxyindol-1-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.3230	uM
(6E,8Z,11Z,14Z,17Z)-5-oxoicosa-6,8,11,14,17-pentaenoic acid	1497846: Agonist activity at human PK-tagged OXER1 expressed in CHOK1 cells assessed as EA-tagged beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation assay	ec50	0.3800	uM
5-(6-chloroindol-1-yl)-5-oxopentanoic acid	736229: Antagonist activity at OXE receptor in human neutrophils assessed as 5-oxo-ETE-induced Ca2+ mobilization incubated for 2 mins prior to 5-oxo-ETE addition measured after 1 min by spectrofluorimetric analysis	ic50	0.4000	uM
5-[6-chloro-2-[(Z)-hex-1-enyl]indol-1-yl]-3-methyl-5-oxopentanoic acid	1180185: Antagonist activity at 5-oxo-ETE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced Ca2+ mobilization incubated for 2 mins prior to 5-oxo-ETE addition by indo-1 staining-based spectrofluorometry	ic50	0.4600	uM
(6E,8Z,10E,12S,14Z)-12-hydroxy-5-oxoicosa-6,8,10,14-tetraenoic acid	1067794: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization by spectrofluorometric analysis	ic50	0.5000	uM
(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid	1410868: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition by fluorescence assay	ic50	0.5000	uM
5-oxo-5-[2-[(Z)-undec-1-enyl]indol-1-yl]pentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.5500	uM
5-(5-chloro-2-hexyl-1-methylindol-3-yl)-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.5660	uM
5-(2-octylindol-1-yl)-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.5700	uM
2-[1-[2-(5-chloro-2-hexyl-1-methylindol-3-yl)-2-oxoethyl]cyclopropyl]acetic acid	1464785: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.5800	uM
5-(5-bromo-2-hexylindol-1-yl)-3-methyl-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.6380	uM
5-oxo-5-(2-undecylindol-1-yl)pentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.7000	uM
2-[1-[2-(5-chloro-2-hexyl-1-methylindol-3-yl)-2-oxoethyl]cyclobutyl]acetic acid	1464785: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.7200	uM
(3R)-5-[5-chloro-2-[(1R)-1-hydroxy-6-phenylhexyl]-1-methylindol-3-yl]-3-methyl-5-oxopentanoic acid	1410867: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	0.7500	uM
5-(2-heptylindol-1-yl)-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	0.7500	uM
3-(5-chloro-2-hexyl-1-methylindole-3-carbonyl)benzoic acid	1464785: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	1.1200	uM
5-(2-hexylindol-1-yl)-5-oxopentanoic acid	1067795: Antagonist activity at OXE receptor (unknown origin) expressed in indo-1 loaded neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins prior to 5-oxo-ETE induction by spectrofluorometric analysis	ic50	1.1300	uM
5-(5-chloroindol-1-yl)-5-oxopentanoic acid	736229: Antagonist activity at OXE receptor in human neutrophils assessed as 5-oxo-ETE-induced Ca2+ mobilization incubated for 2 mins prior to 5-oxo-ETE addition measured after 1 min by spectrofluorimetric analysis	ic50	1.1700	uM
5-(5-chloro-2-hexyl-1-methylindol-3-yl)-3,3-dimethyl-5-oxopentanoic acid	1464785: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	1.3300	uM
4-(5-chloro-2-hexyl-1-methylindole-3-carbonyl)benzoic acid	1464785: Antagonist activity at OXE receptor in human neutrophils assessed as inhibition of 5-oxo-ETE-induced calcium mobilization incubated for 2 mins followed by 5-oxo-ETE addition measured after 1 min by fluorescence assay	ic50	1.3600	uM

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	2
Tobacco Smoke Pollution	decreases expression, increases methylation	2
aristolochic acid I	increases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
terbufos	increases methylation	1
ferrous chloride	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
clothianidin	decreases expression	1
eprenetapopt	affects expression, affects reaction	1
Allergens	increases expression	1
Fonofos	increases methylation	1
Parathion	increases methylation	1
Tetrachlorodibenzodioxin	affects expression	1
Valproic Acid	increases methylation	1
Cyclosporine	decreases methylation	1
Sodium Selenite	decreases expression	1
Okadaic Acid	decreases expression	1

ChEMBL screening assays

29 unique, capped per target: 22 functional, 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1686896	Functional	Agonist activity at 5-oxo-ETE receptor in human neutrophils assessed as stimulation of ca2+ mobilization at 100 nM in presence of 5-oxo-ETE	5-oxo-15-HETE: total synthesis and bioactivity. — Bioorg Med Chem Lett
CHEMBL3117762	Binding	Antagonist activity at OXE receptor (unknown origin) expressed in neutrophils assessed as inhibition of 5-oxo-ETE-induced cell migration after 2 hrs by hematoxylin/chromotrope 2R staining-based microscopic analysis	Inhibition of 5-oxo-6,8,11,14-eicosatetraenoic acid-induced activation of neutrophils and eosinophils by novel indole OXE receptor antagonists. — J Med Chem

Cellosaurus cell lines

4 cell lines: 3 spontaneously immortalized cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_H489	CHO-K1/Galpha15/OXER1	Spontaneously immortalized cell line	Female
CVCL_KV63	cAMP Hunter CHO-K1 OXER1 Gi	Spontaneously immortalized cell line	Female
CVCL_KY71	PathHunter CHO-K1 OXER1 beta-arrestin	Spontaneously immortalized cell line	Female
CVCL_LB03	PathHunter U2OS OXER1 Total GPCR Internalization	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.